Idiopathic Thrombocytopenic Purpura Market

 Market Overview:

The 7 major idiopathic thrombocytopenic purpura markets are expected to exhibit a CAGR of 4.15% during 2024-2034.

The idiopathic thrombocytopenic purpura market has been comprehensively analyzed in IMARC's new report titled "Idiopathic Thrombocytopenic Purpura Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Idiopathic thrombocytopenic purpura (ITP) is a blood disorder characterized by low platelet counts, which can cause a variety of symptoms related to abnormal bleeding and bruising. Some of the most common indications include easy bruising, nosebleeds, prolonged bleeding after injury or surgery, bleeding gums, blood in urine or stool, petechiae (small red or purple spots on the skin), etc. In many cases, females with ITP may also experience heavy menstrual bleeding, excessive bleeding during childbirth, or bleeding in the brain, which can be life-threatening. The diagnosis typically involves a thorough medical history, physical examination, and blood tests to assess platelet counts. Various additional procedures, such as a bone marrow biopsy, may be recommended to confirm the prognosis or rule out further conditions. In some cases, several imaging tests are also used to check for bleeding or other complications related to low platelet counts. A diagnosis of ITP is typically made if a person has a platelet count of less than 100,000 per microliter of blood and no other underlying medical conditions that could cause thrombocytopenia.

The increasing prevalence of autoimmune disorders in which the immune system mistakenly attacks and destroys the blood platelets is primarily driving the idiopathic thrombocytopenic purpura market. Besides this, the rising incidence of several associated risk factors, such as viral and bacterial infections, certain medical conditions like lupus and rheumatoid arthritis, blood transfusions, etc., is also propelling the market growth. Furthermore, the widespread adoption of corticosteroids as a first-line treatment since they can rapidly improve platelet counts by suppressing the immune response that destroys platelets is creating a positive outlook for the market. Apart from this, the inflating demand for thrombopoietin receptor agonists, including romiplostim and eltrombopag, for increasing platelet counts in patients with chronic ITP who have not responded to other treatments is acting as another significant growth-inducing factor. Additionally, numerous key players are exploring the use of biomarkers to predict response to treatment and identify patients who are at risk of developing more severe forms of the disease. This, in turn, is further augmenting the market growth. Moreover, the emerging popularity of platelet growth factors, such as eltrombopag and romiplostim, which can aid in reducing the likelihood of bleeding incidences, is expected to drive the idiopathic thrombocytopenic purpura market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the idiopathic thrombocytopenic purpura market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for idiopathic thrombocytopenic purpura and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the idiopathic thrombocytopenic purpura market in any manner.

Recent Developments:

• In June 2024, HUTCHMED (China) Limited declared that The Lancet Haematology had published the findings of ESLIM-01, HUTCHMED's Phase III trial of sovleplenib (HMPL-523) in adult patients with primary immune thrombocytopenia (ITP) in China.
• In March 2024, Takeda reported positive topline results from a Phase 2 randomized, double-blind, placebo-controlled research that assessed the safety, tolerability, and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia. Mezagitamab is a completely human immunoglobulin IgG1 monoclonal antibody (mAb) that has a high affinity for CD38-expressing cells (including plasmablasts, plasma cells, and natural killer cells), depleting them.
• In November 2023, Takeda reported that ADZYNMA (ADAMTS13, recombinant-krhn) has been approved by the U.S. FDA for the preventative and on-demand treatment of congenital thrombotic thrombocytopenic purpura (cTTP) in adults and children. ADZYNMA, the first and only FDA-approved recombinant ADAMTS13 (rADAMTS13) protein, addresses an unmet medical need in persons with cTTP by replacing the missing ADAMTS13 enzyme.
• In November 2023, argenx SE released topline results of the ADVANCE-SC study assessing VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP).

Key Highlights:

• The annual incidence of ITP is around 5 cases per 100,000 children and 2 cases per 100,000 adults.
• In the United States, the annual incidence of ITP is estimated to be 3.3 per 100,000 people.
• In Europe, the annual incidence of ITP among adults is estimated to be between 1 and 4 per 100,000.
• Adults over the age of 60 have a higher prevalence of ITP because they are more likely to develop the disease's chronic form.
• ITP is most common in children between the ages of one and six years old.
• Approximately 0.5% to 1% of children suffering from ITP experience intracranial hemorrhage, and half of those cases lead to fatality.

Drugs:

Carimune NF Nanofiltered Immune Globulin Intravenous (Human) is a sterile, highly pure polyvalent antibody preparation that contains all IgG antibodies found in the donor population. This therapeutic candidate is appropriate for intravenous usage after being treated with acid pH and trace levels of pepsin.

PRN1008 is an oral, reversible covalent BTK inhibitor (Bruton's Tyrosine Kinase, which is involved in B-cell signaling and inflammatory pathways in most white blood cell types except T-cells and plasma cells). Principia's Tailored Covalency technology optimizes the safety and efficacy profile, resulting in sustained and reversible action at the target location and quick elimination from the body. This technique restricts PRN1008's systemic exposure while allowing for rapid clinical reversibility of immune system effects.

Rozanolixizumab is a humanized monoclonal antibody that is injected subcutaneously and binds to human FcRn with high affinity. It has been designed to disrupt the interaction of FcRn with IgG, reducing IgG recycling and promoting the elimination of pathogenic IgG autoantibodies.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the idiopathic thrombocytopenic purpura market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the idiopathic thrombocytopenic purpura market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current idiopathic thrombocytopenic purpura marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance 
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the idiopathic thrombocytopenic purpura market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the idiopathic thrombocytopenic purpura market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the idiopathic thrombocytopenic purpura market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura across the seven major markets?
• What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of idiopathic thrombocytopenic purpura by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with idiopathic thrombocytopenic purpura across the seven major markets?
• What is the size of the idiopathic thrombocytopenic purpura patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of idiopathic thrombocytopenic purpura?
• What will be the growth rate of patients across the seven major markets?
   

Idiopathic Thrombocytopenic Purpura: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for idiopathic thrombocytopenic purpura drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the idiopathic thrombocytopenic purpura market?
• What are the key regulatory events related to the idiopathic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by status related to the idiopathic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by phase related to the idiopathic thrombocytopenic purpura market?
• What is the structure of clinical trial landscape by route of administration related to the idiopathic thrombocytopenic purpura market?